Skip to content
drillr.ai

IMNM

Immunome, Inc.

NASDAQ · USHealthcareBiotechnology
$22.16-0.72%

Price as of Jul 20, 2026

IMNM news

Immunome, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

    Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors * IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. * The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-

    Business Wire ·

  2. Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

    Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors * PDUFA target action date set for April 28, 2027 * Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved Immunome, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimmunome.com%2F&esheet=54566700&newsitemid=20260708283482&lan=en-US&anchor=Immunome%2C+Inc.&index=1&md5=d334227e04f8c2b86fb

    Business Wire ·

  3. Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen ne

    Business Wire ·

  4. Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

    Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors * IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload * Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively Imm

    Business Wire ·

  5. Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

    Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting * Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints * Varegacestat demonstrated statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as the first evaluation at week 4 * Progression-free survival b

    Business Wire ·

  6. Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

    Immunome Reports First Quarter 2026 Financial Results and Provides Business Update * New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors * Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting * Phase 1 study ongoing for IM-1021, with initial lymphoma data expected in 2026 * Investig

    Business Wire ·

  7. Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

    Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors * New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) * Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% * Detailed Phase 3 RINGSIDE data selected for oral presentation at th

    Business Wire ·

  8. Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

    Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Cl

    Business Wire ·

  9. Immunome Reports Full Year 2025 Financial Results and Provides Business Update

    Immunome Reports Full Year 2025 Financial Results and Provides Business Update * New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 * IM-1021 Phase 1 ongoing with initial data expected in 2026 * Three IND submissions for solid tumor-targeted ADC programs planned in 2026 * Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028 Immunome, Inc. (https://cts.businesswire.com/ct/

    Business Wire ·